Efficacy of Upadacitinib After NECS in Vitiligo
A legfontosabb adatok
- Ki végzi
- Jilin University
- Hol
- Changchun (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 60 fő, tervezett
- Kezdés
- 2024. dec. 4.
- Várható befejezés
- 2029. jún. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Upadacitinib 15 MG
- A regiszteradat frissítve
- 2024. december 27.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with stable non-segmented vitiligo who will have a skin cell transplant (NECS). Some will also take upadacitinib afterwards.
- Életkor
- 18 to 60 years
- Nem
- All sexes
- A betegség stádiuma
- Non-segmented vitiligo, stable for more than one year (no spreading, no new patches). Total affected skin (BSA) ≤30%, with a fairly flat target patch not on the hands, feet, perineum, lips, joints or around the anus.
- Korábbi kezelés
- No laser or light therapy for vitiligo within 4 weeks. No oral or systemic vitiligo medicines within 4 weeks. No JAK inhibitor or biologic within 12 weeks or 5 half-lives, whichever is longer.
A részvétel fő kizáró okai
- Infection with HBV, HCV, HIV or syphilis, or active tuberculosis or TB treatment within 1 year
- Other active skin disease or skin infection, or a serious infection within one month
- Liver problems (bilirubin, AST or ALT ≥ 2 × ULN) or kidney problems (eGFR <45 mL/min or on dialysis)
- Cancer now or in the past, except treated non-spreading basal or squamous cell skin cancer; current thyroid disease
- Pregnant or breastfeeding women
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- Participants who can sign the informed consent
- Participants aged 18-60 years (both men and women) at the time of signing the informed consent
- Non-segmented vitiligo
- Vitiligo affected area should meet the following two criteria:; (1) containing the target area (relatively flat vitiligo lesions except of the hands and feet, perineum, lips, joints, perianal); (2) total BSA involvement ≤30% 5. Clinically stable for more than one year (stable refers to the original lesion no longer expanding and no new lesions appearing)
- All fertile women had to be willing to use at least one highly effective method of contraception from the time they signed informed consent through the final follow-up visit
- Participants must be willing and able to adhere to scheduled visits and scheduled treatments, laboratory tests, and other study procedures
Ki nem vehet részt
- Participants had a clinically significant infection (requiring hospitalization and parenteral treatment with antibiotics, antiviral agents, or antifungal agents for more than 3 days) within one month of the screening period or an active infection for which they were receiving treatment during the screening period
- Participants had active Tuberculosis or were receiving anti-Tuberculosis treatment, or had received anti-Tuberculosis treatment within 1 year
- Participants who received any laser or phototherapy for vitiligo within 4 weeks before baseline
- Participants who received oral or systemic medications (e.g., glucocorticoids, cyclosporine, methotrexate, tacrolimus, Chinese medicine, etc.) aimed at controlling/improving vitiligo symptoms within 4 weeks before baseline
- Participants who had received JAK inhibitor therapy (including, but not limited to Ruxolitinib, Tofacitinib, Baricitinib, Upadacinib, etc.) within 12 weeks or 5 half-lives before baseline, whichever was longer
- Participants who had been enrolled in another intervention clinical trial within 4 weeks before the baseline visit or who were within 5 half-lives of the last dose of the intervention drug at baseline
- Any active skin lesions (e.g. psoriasis, dermatitis, skin ulceration, etc.) or skin infections (bacterial, fungal, viral, etc.) which may interfere with the assessment of vitiligo at screening
- Infected with HBV or HCV or HIV or syphilis
- Participants with malignancy or with a history of malignancy other than adequately treated or resected nonmetastatic basal cell carcinoma or squamous cell carcinoma
- Participants with current thyroid disease or undergoing thyroid replacement therapy
- Participants with a history of mental illness, such as anxiety or depression, who were assessed by the investigator to be unfit to participate in the study
- Any other condition that the investigator considered might render the subject ineligible for inclusion in the study
- Hepatic dysfunction (Total bilirubin ≥ 2 × ULN, AST≥2 × ULN, ALT ≥ 2 × ULN) at screening
- Renal impairment ( eGFR of <45 mL/min or receiving dialysis) at screening
- Pregnant or lactating female participants
- Participants who had used any biologic agent within 12 weeks or 5 half-lives before baseline, whichever was longer
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 60 év között vagy?
Helyszínek itt: Kína
- Department of Dermatology and Venerology, The First Hospital of Jilin University, No. 1 Xinmin StreetChangchun, KínaContact: Bing Han, MDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to investigate the efficacy of upadacitinib after NECS in participants with vitiligo. The main question it aims to answer is: whether the short time use of upadacitinib after NECS will improve NECS efficacy. Participants in the experimental group will receive upadacitinib after NECS, while Participants in the control group will receive NECS only.
A vizsgálat 2 csoportja
- AA vizsgált kezelés
upadacitinib after autologous non-cultured epidermal cell suspension transplantation
Kezelés: Upadacitinib 15 MG
- BNincs vizsgálati kezelés, összehasonlításként
autologous non-cultured epidermal cell suspension transplantation
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy of Upadacitinib After Autologous Non-cultured Epidermal Cell Suspension Transplantation in Vitiligo Participants -- a Pilot, Random, Observer Blinded, Comparative Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06454461: ki vehet részt
- A regiszteradat frissítve
- 2024. december 27.